Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma led by Sofinnova Partners and co-led by Intermediate Capital Group
    www.anderapartners.com
  • Proteros receives minority investment from private equity firm Inflexion
    www.proteros.com
  • Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
    www.spexisbio.com
  • InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
    www.inflarx.de
  • Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
    www.volta-medical.com
  • Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action
    www.abivax.com
  • LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
    www.leon-nanodrugs.com
  • MAINZ BIOMED PROVIDES YEAR-END 2022 CORPORATE REVIEW
    www.mainzbiomed.com
  • Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
    www.newron.com
  • Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022
    www.destinypharma.com